Genc Mehmet, Can Murat, Guven Berrak, Cinar Saniye, Buyukuysal Cagatay, Acikgoz Bilgehan, Mungan Ayca Gorkem, Acikgoz Serefden
Department of Biochemistry, Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
Department of Dermatology, Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
Indian J Clin Biochem. 2017 Mar;32(1):90-94. doi: 10.1007/s12291-016-0570-0. Epub 2016 May 6.
Psoriasis patients are determined to have a high ratio of coronary artery calcification. Fetuin-A and osteoprotegerin are systemic calcification inhibitors and related to vascular calcification and cardiovascular mortality. In this study we investigated the relationship between fetuin-A and osteoprotegerin levels in psoriasis patients. The study included 40 healthy volunteers and 40 psoriasis patients. Venous blood were collected from healthy volunteers and psoriasis patients in order to search the fetuin-A and osteoprotegerin levels. Disease severity were grouped as mild, moderate and severe according to psoriasis area and severity index (PASI). The relationship between fetuin-A and osteoprotegerin levels and clinical features as sex, PASI and presence of psoriatic arthritis were analyzed. Fetuin-A levels in psoriasis patients were statistically lower than the control group ( < 0.001). In serum osteoprotegerin levels, no statistically significant difference was found in two groups ( > 0.05). Serum fetuin-A and osteoprotegerin level differences were not statistically significant between patients with psoriatic arthritis history and those without. When we grouped patients in respect of their sexes fetuin-A and osteoprotegerin levels of males and females were not significantly different ( > 0.05). No correlation was detected between the ages and PASI scores and the fetuin-A and osteoprotegerin levels of patients. As a result fetuin-A levels in psoriasis patients are found to be low but not related to disease severity. In the light of our results we concluded that fetuin-A may have a role in psoriasis pathogenesis and may contribute to the calcification process developed in psoriasis.
银屑病患者被确定有较高比例的冠状动脉钙化。胎球蛋白-A和骨保护素是全身钙化抑制剂，与血管钙化和心血管死亡率相关。在本研究中，我们调查了银屑病患者胎球蛋白-A和骨保护素水平之间的关系。该研究纳入了40名健康志愿者和40名银屑病患者。采集健康志愿者和银屑病患者的静脉血以检测胎球蛋白-A和骨保护素水平。根据银屑病面积和严重程度指数（PASI）将疾病严重程度分为轻度、中度和重度。分析胎球蛋白-A和骨保护素水平与性别、PASI及银屑病关节炎的存在等临床特征之间的关系。银屑病患者的胎球蛋白-A水平在统计学上低于对照组（<0.001）。在血清骨保护素水平方面，两组之间未发现统计学上的显著差异（>0.05）。有银屑病关节炎病史的患者与无银屑病关节炎病史的患者之间，血清胎球蛋白-A和骨保护素水平差异无统计学意义。当我们按性别对患者进行分组时，男性和女性的胎球蛋白-A和骨保护素水平无显著差异（>0.05）。未检测到患者的年龄和PASI评分与胎球蛋白-A和骨保护素水平之间存在相关性。结果发现，银屑病患者的胎球蛋白-A水平较低，但与疾病严重程度无关。根据我们的结果，我们得出结论，胎球蛋白-A可能在银屑病发病机制中起作用，并可能促成银屑病中发生的钙化过程。
